US OptionsDetailed Quotes
REPL241220P20000
- 6.30
- 0.000.00%
15min DelayTrading Dec 2 11:34 ET
0.00High0.00Low
0.00Open6.30Pre Close0 Volume1 Open Interest20.00Strike Price0.00Turnover241.58%IV-10.57%PremiumDec 20, 2024Expiry Date7.61Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8952Delta0.0441Gamma1.60Leverage Ratio-0.0498Theta-0.0029Rho-1.43Eff Leverage0.0031Vega
Replimune Stock Discussion
Sign in to post a comment
The market climbed Friday after a week of waiting and reacting to Nvidia earnings and Bitcoin's all-time highs.
The market overall advanced Friday. Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ traded +0.35%, the $Dow Jones Industrial Average (.DJI.US)$ climbed 0.97%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.16%.
MACRO
In macroeconomics, S&P Global released its composite and service PMI. Composite came in at a two-year high, 55.3...
The market overall advanced Friday. Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ traded +0.35%, the $Dow Jones Industrial Average (.DJI.US)$ climbed 0.97%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.16%.
MACRO
In macroeconomics, S&P Global released its composite and service PMI. Composite came in at a two-year high, 55.3...
56
7
3
Good morning, traders. Happy Friday, November 22nd. Without the news and animal spirits moving markets, you will not make it through today. My name is Kevin Travers, and the S&P 500 and market climbed this morning, here is what's moving:
$Super Micro Computer (SMCI.US)$ climbed 15%, after earlier this week, the firm said it submitted a plan to release its six-month delayed 10k with a new auditor, BDO USA, and filed for a time extension to file it...
$Super Micro Computer (SMCI.US)$ climbed 15%, after earlier this week, the firm said it submitted a plan to release its six-month delayed 10k with a new auditor, BDO USA, and filed for a time extension to file it...
37
9
3
.
$Replimune (REPL.US)$ Reuters· 3 mins ago
Replimune Receives Breakthrough Therapy Designation for Rp1 and Submits Rp1 Biologics License Application to the FDA Under the Accelerated Approval Pathway
Replimune Receives Breakthrough Therapy Designation for Rp1 and Submits Rp1 Biologics License Application to the FDA Under the Accelerated Approval Pathway
$Replimune (REPL.US)$ Replimune: Positive Topline Primary Analysis Data by Independent Central Review From Ignyte Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma! Intends to submit BLA in 2H 2024
$Replimune (REPL.US)$
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune presented positive data from its RP1 and RP2 clinical programs at the 2024 ASCO Annual Meeting. The IGNYTE trial showed a 32.7% overall response rate (ORR) for RP1 plus nivolumab in anti-PD-1 failed melanoma, with responses lasting over six months and a median duration exceeding 36 months. RP2, both as monotherapy and in co...
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Replimune presented positive data from its RP1 and RP2 clinical programs at the 2024 ASCO Annual Meeting. The IGNYTE trial showed a 32.7% overall response rate (ORR) for RP1 plus nivolumab in anti-PD-1 failed melanoma, with responses lasting over six months and a median duration exceeding 36 months. RP2, both as monotherapy and in co...
No comment yet
Trader TD : amazing! so do I buy or sell?
Laine Ford : the stock only wall street stock is all good stock to have and.hold make that money
103677010 : noted
l0lBElBgG : k
Laine Ford : that all okay stock
View more comments...